166 related articles for article (PubMed ID: 27729458)
21. Targeting aberrant PI3K/Akt activation by PI103 restores sensitivity to TRAIL-induced apoptosis in neuroblastoma.
Opel D; Naumann I; Schneider M; Bertele D; Debatin KM; Fulda S
Clin Cancer Res; 2011 May; 17(10):3233-47. PubMed ID: 21355080
[TBL] [Abstract][Full Text] [Related]
22. Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity.
Chen Z; Wang Z; Pang JC; Yu Y; Bieerkehazhi S; Lu J; Hu T; Zhao Y; Xu X; Zhang H; Yi JS; Liu S; Yang J
Sci Rep; 2016 Jul; 6():29090. PubMed ID: 27378523
[TBL] [Abstract][Full Text] [Related]
23. FGFR2 loss sensitizes MYCN-amplified neuroblastoma CHP134 cells to CHK1 inhibitor-induced apoptosis.
Ando K; Ohira M; Takada I; Cázares-Ordoñez V; Suenaga Y; Nagase H; Kobayashi S; Koshinaga T; Kamijo T; Makishima M; Wada S
Cancer Sci; 2022 Feb; 113(2):587-596. PubMed ID: 34807483
[TBL] [Abstract][Full Text] [Related]
24. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
[TBL] [Abstract][Full Text] [Related]
25. MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.
García-García C; Rivas MA; Ibrahim YH; Calvo MT; Gris-Oliver A; Rodríguez O; Grueso J; Antón P; Guzmán M; Aura C; Nuciforo P; Jessen K; Argilés G; Dienstmann R; Bertotti A; Trusolino L; Matito J; Vivancos A; Chicote I; Palmer HG; Tabernero J; Scaltriti M; Baselga J; Serra V
Clin Cancer Res; 2015 Dec; 21(24):5499-5510. PubMed ID: 26272063
[TBL] [Abstract][Full Text] [Related]
26. EGFR and MEK Blockade in Triple Negative Breast Cancer Cells.
Maiello MR; D'Alessio A; Bevilacqua S; Gallo M; Normanno N; De Luca A
J Cell Biochem; 2015 Dec; 116(12):2778-85. PubMed ID: 25959272
[TBL] [Abstract][Full Text] [Related]
27. Mechanisms of Entrectinib Resistance in a Neuroblastoma Xenograft Model.
MacFarland SP; Naraparaju K; Iyer R; Guan P; Kolla V; Hu Y; Tan K; Brodeur GM
Mol Cancer Ther; 2020 Mar; 19(3):920-926. PubMed ID: 31871269
[TBL] [Abstract][Full Text] [Related]
28. RAS-MAPK Pathway-Driven Tumor Progression Is Associated with Loss of CIC and Other Genomic Aberrations in Neuroblastoma.
Eleveld TF; Schild L; Koster J; Zwijnenburg DA; Alles LK; Ebus ME; Volckmann R; Tijtgat GA; van Sluis P; Versteeg R; Molenaar JJ
Cancer Res; 2018 Nov; 78(21):6297-6307. PubMed ID: 30115695
[TBL] [Abstract][Full Text] [Related]
29. Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome.
Padovan-Merhar OM; Raman P; Ostrovnaya I; Kalletla K; Rubnitz KR; Sanford EM; Ali SM; Miller VA; Mossé YP; Granger MP; Weiss B; Maris JM; Modak S
PLoS Genet; 2016 Dec; 12(12):e1006501. PubMed ID: 27997549
[TBL] [Abstract][Full Text] [Related]
30. Differential sensitivity of chemoresistant neuroblastoma subtypes to MAPK-targeted treatment correlates with ERK, p53 expression, and signaling response to U0126.
Eppstein AC; Sandoval JA; Klein PJ; Woodruff HA; Grosfeld JL; Hickey RJ; Malkas LH; Schmidt CM
J Pediatr Surg; 2006 Jan; 41(1):252-9. PubMed ID: 16410143
[TBL] [Abstract][Full Text] [Related]
31. Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis.
Wang Y; Wang L; Guan S; Cao W; Wang H; Chen Z; Zhao Y; Yu Y; Zhang H; Pang JC; Huang SL; Akiyama Y; Yang Y; Sun W; Xu X; Shi Y; Zhang H; Kim ES; Muscal JA; Lu F; Yang J
Sci Rep; 2016 Jan; 6():19423. PubMed ID: 26786851
[TBL] [Abstract][Full Text] [Related]
32. PIM Kinases Are a Potential Prognostic Biomarker and Therapeutic Target in Neuroblastoma.
Brunen D; de Vries RC; Lieftink C; Beijersbergen RL; Bernards R
Mol Cancer Ther; 2018 Apr; 17(4):849-857. PubMed ID: 29440296
[TBL] [Abstract][Full Text] [Related]
33. Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma.
Krytska K; Ryles HT; Sano R; Raman P; Infarinato NR; Hansel TD; Makena MR; Song MM; Reynolds CP; Mossé YP
Clin Cancer Res; 2016 Feb; 22(4):948-60. PubMed ID: 26438783
[TBL] [Abstract][Full Text] [Related]
34. Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors.
Malone CF; Kim M; Alexe G; Engel K; Forman AB; Robichaud A; Conway AS; Goodale A; Meyer A; Khalid D; Thayakumar A; Hatcher JM; Gray NS; Piccioni F; Stegmaier K
Cancer Res; 2023 Jan; 83(2):285-300. PubMed ID: 36398965
[TBL] [Abstract][Full Text] [Related]
35. Improved therapy for neuroblastoma using a combination approach: superior efficacy with vismodegib and topotecan.
Chaturvedi NK; McGuire TR; Coulter DW; Shukla A; McIntyre EM; Sharp JG; Joshi SS
Oncotarget; 2016 Mar; 7(12):15215-29. PubMed ID: 26934655
[TBL] [Abstract][Full Text] [Related]
36. Select Bcl-2 antagonism restores chemotherapy sensitivity in high-risk neuroblastoma.
Tanos R; Karmali D; Nalluri S; Goldsmith KC
BMC Cancer; 2016 Feb; 16():97. PubMed ID: 26874859
[TBL] [Abstract][Full Text] [Related]
37. Polyamine Antagonist Therapies Inhibit Neuroblastoma Initiation and Progression.
Evageliou NF; Haber M; Vu A; Laetsch TW; Murray J; Gamble LD; Cheng NC; Liu K; Reese M; Corrigan KA; Ziegler DS; Webber H; Hayes CS; Pawel B; Marshall GM; Zhao H; Gilmour SK; Norris MD; Hogarty MD
Clin Cancer Res; 2016 Sep; 22(17):4391-404. PubMed ID: 27012811
[TBL] [Abstract][Full Text] [Related]
38. The combined therapeutic effects of bortezomib and fenretinide on neuroblastoma cells involve endoplasmic reticulum stress response.
Pagnan G; Di Paolo D; Carosio R; Pastorino F; Marimpietri D; Brignole C; Pezzolo A; Loi M; Galietta LJ; Piccardi F; Cilli M; Nico B; Ribatti D; Pistoia V; Ponzoni M
Clin Cancer Res; 2009 Feb; 15(4):1199-209. PubMed ID: 19228726
[TBL] [Abstract][Full Text] [Related]
39. Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment.
Lambertz I; Kumps C; Claeys S; Lindner S; Beckers A; Janssens E; Carter DR; Cazes A; Cheung BB; De Mariano M; De Bondt A; De Brouwer S; Delattre O; Gibbons J; Janoueix-Lerosey I; Laureys G; Liang C; Marchall GM; Porcu M; Takita J; Trujillo DC; Van Den Wyngaert I; Van Roy N; Van Goethem A; Van Maerken T; Zabrocki P; Cools J; Schulte JH; Vialard J; Speleman F; De Preter K
Clin Cancer Res; 2015 Jul; 21(14):3327-39. PubMed ID: 25805801
[TBL] [Abstract][Full Text] [Related]
40. High-risk neuroblastoma with NF1 loss of function is targetable using SHP2 inhibition.
Cai J; Jacob S; Kurupi R; Dalton KM; Coon C; Greninger P; Egan RK; Stein GT; Murchie E; McClanaghan J; Adachi Y; Hirade K; Dozmorov M; Glod J; Boikos SA; Ebi H; Hao H; Caponigro G; Benes CH; Faber AC
Cell Rep; 2022 Jul; 40(4):111095. PubMed ID: 35905710
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
